Progress in antithrombotic strategy for atrial fibrillation in patients with cerebral microbleeds

于垚,李华军,李永杰
DOI: https://doi.org/10.11817/j.issn.1673-9248.2022.01.003
2022-01-01
Abstract:Cerebral microbleeds (CMBs) are caused by cerebral small vessel diseases with high prevalence. Emerging evidence shows that CMBs are an independent risk factor of intracranial hemorrhage and hemorrhagic transformation after ischemic stroke. Hemorrhage is the biggest concern of antithrombotic therapy. Therefore, antithrombotic therapy is one of the major challenges for atrial fibrillation in patients with CMBs. However, so far there is no high-quality clinical randomized controlled trial to evaluate the benefits and risks of the patients taking antithrombotic therapy. This article reviews the relevant studies to provide evidence for clinicians to antithrombotic strategy according to the clinical characteristics of patients, so as to maximize the benefits of patients.
What problem does this paper attempt to address?